


Healthcare News Roundup: Oncology
HSMN NewsFeed - 17 Jul 2013
Rexahn Pharmaceuticals In-Licenses Breakthrough Oncology Drug Delivery Platform
Rexahn Pharmaceuticals In-Licenses Breakthrough Oncology Drug Delivery Platform
HSMN NewsFeed - 8 Jul 2013
Market Access Granted in Italy for Aggressive non-Hodgkin Lymphoma Treatment, PIXUVRI(R) (pixantrone)
Market Access Granted in Italy for Aggressive non-Hodgkin Lymphoma Treatment, PIXUVRI(R) (pixantrone)
HSMN NewsFeed - 3 Jul 2013
Seattle's Swedish Cancer Institute Acquires Four Elekta Versa HD Radiation Therapy Systems
Seattle's Swedish Cancer Institute Acquires Four Elekta Versa HD Radiation Therapy Systems
HSMN NewsFeed - 2 Jul 2013
ARIAD Announces Marketing Authorization for Iclusig(R) (ponatinib) in the European Union
ARIAD Announces Marketing Authorization for Iclusig(R) (ponatinib) in the European Union
HSMN NewsFeed - 25 Jun 2013
IsoRay Announces a New International Distributor in Australia and New Zealand
IsoRay Announces a New International Distributor in Australia and New Zealand
HSMN NewsFeed - 24 Jun 2013
XTANDI(TM) (Enzalutamide) Authorized in the European Union for Advanced Prostate Cancer
XTANDI(TM) (Enzalutamide) Authorized in the European Union for Advanced Prostate Cancer
HSMN NewsFeed - 13 Jun 2013
FDA Approves Amgen's XGEVA(R) (denosumab) For The Treatment Of Giant Cell Tumor Of Bone
FDA Approves Amgen's XGEVA(R) (denosumab) For The Treatment Of Giant Cell Tumor Of Bone
HSMN NewsFeed - 13 Jun 2013
First U.S. Center to Treat a Patient with the new CyberKnife(R) M6(TM) System
First U.S. Center to Treat a Patient with the new CyberKnife(R) M6(TM) System
HSMN NewsFeed - 13 Jun 2013
PRISM Pharma Closes $15 million Series C Financing to Advance PRI-724 into Non-oncology Indications
PRISM Pharma Closes $15 million Series C Financing to Advance PRI-724 into Non-oncology Indications
HSMN NewsFeed - 12 Jun 2013
Amgen Announces Top-Line Results Of Phase 3 Trebananib (AMG 386) TRINOVA-1 Trial In Recurrent Ovarian Cancer
Amgen Announces Top-Line Results Of Phase 3 Trebananib (AMG 386) TRINOVA-1 Trial In Recurrent Ovarian Cancer
HSMN NewsFeed - 10 Jun 2013
Elekta-Equra Health Partnership to Increase South African Cancer Patients’ Access to Radiation Therapy
Elekta-Equra Health Partnership to Increase South African Cancer Patients’ Access to Radiation Therapy
HSMN NewsFeed - 27 May 2013
Leeds’ St James’s Institute of Oncology Acquires Two Elekta Versa HD Radiotherapy Systems
Leeds’ St James’s Institute of Oncology Acquires Two Elekta Versa HD Radiotherapy Systems
